**What is already known about this topic?**•In the UK, Rheumatology Clinical Nurse Specialists conduct nurse-led clinics which provide follow-up care to patients with rheumatoid arthritis including monitoring, patient education and psychosocial support.•Research has shown positive outcomes of nurse-led clinics but the UK studies have several limitations and lack generalisability and evidence of cost-effectiveness.

**What this paper adds**•This paper outlines a protocol and methodology of a randomised controlled trial being conducted to demonstrate the outcomes and cost-effectiveness of nurse-led care in rheumatoid arthritis.•This is the first UK multi-centred RCT of effectiveness of nurse-led care in rheumatology.•This is the first UK study of cost-effectiveness of nurse-led care in rheumatology.

1. Background {#sec0005}
=============

During the past 20 years the rise in the number of patients with arthritis, understaffing of medical services and reduced junior hospital doctors' working hours have prompted the rheumatology community in the United Kingdom (UK) to reassess how patient services are provided. These pressures have meant that whilst essential medical provision remains intact, it is often at the expense of the psychological, social, rehabilitative and educational needs that are so necessary to enhance patient outcomes ([@bib0100]). To counter these problems, rheumatology units increasingly augment the multidisciplinary team with clinical nurse specialists who are senior nurses, specially trained to undertake extended roles. By taking on some of the technical and patient management activities that were previously the sole responsibility of rheumatologists, these nurses allow rheumatologists to concentrate on the more complex tasks such as differential diagnosis for which they are uniquely trained ([@bib0010]).

Despite this innovative development, the evidence of effectiveness of nurse-led rheumatology clinics is limited. Our literature search produced no systematic review of nurse-led care effectiveness in rheumatology. Yet there were several systematic reviews of effectiveness in other chronic diseases such as diabetes ([@bib0025]), coronary heart diseases ([@bib0135]) and chronic obstructive pulmonary disease ([@bib0180]). Our recent review ([@bib0110]) revealed seven randomised controlled trials (RCTs) of effectiveness of nurse-led care in rheumatology; four of which were in rheumatoid arthritis ([@bib0055; @bib0070; @bib0160; @bib0195]), two in osteoarthritis ([@bib0065; @bib0225]) and one in fibromyalgia ([@bib0080]). In addition there was an economic evaluation of nurse-led care in rheumatoid arthritis ([@bib0200]). Of the seven RCTs of effectiveness, two were from The Netherlands and five were from the UK. The Dutch team also undertook the economic evaluation.

The majority of the RCTs were in rheumatoid arthritis as this is the disease that the majority of nurses are involved with. The outcomes of patients under nurse-led care were compared to those of the rheumatologist ([@bib0055; @bib0070]), in-patient team and day-patient team care ([@bib0195]) and staff nurse working under a rheumatologist ([@bib0160]). The primary outcomes in these studies were disease activity, functional status, health status and coping with rheumatoid arthritis. The results of disease activity showed that the effects of nurse-led care were not significantly different from those of the comparators ([@bib0055; @bib0070; @bib0195]) and in one study nurse-led care had better effects on disease activity ([@bib0160]). The effects of nurse-led care on functional status were not different from those of in-patient team or day-patient team care ([@bib0195]). Nurse-led care demonstrated better effects than standard care on health status and coping with rheumatoid arthritis ([@bib0160]). The economic analysis ([@bib0200]) concluded that nurse-led care provided equivalent quality of life and utility at a lower cost.

The osteoarthritis RCTs demonstrated better nurse-led care effects in pain control ([@bib0065]) and no difference in coping with arthritis ([@bib0225]). In diagnosing fibromyalgia, nurse-led diagnosis showed excellent agreement with that of the rheumatologist and this agreement was maintained over 24 months ([@bib0080]).

Despite showing positive results, the RCTs of effectiveness of nurse-led care in rheumatoid arthritis have several limitations. The Dutch study ([@bib0195]) was the only multicentre study but it did not compare like with like as there was a disparity in favour of day care and in-patient treatments in the number of visits, hours of treatment and intensity of care. Also, the nurse-led care cohort was less impaired and had a better quality of life at the start of the study, making it more difficult to demonstrate a significant difference between the groups on completion. The sequential studies undertaken in Leeds ([@bib0055; @bib0065; @bib0070]) and Stoke-On-Trent ([@bib0160]) are the only work to date that validates nurse-led rheumatology clinics in the UK. Unfortunately, the Leeds studies also have their limitations, as all were undertaken in one clinic managed by the same rheumatology nurse, one consultant rheumatologist and four junior doctors. In addition, the sample sizes were small and there is no confirmation that these results are reproducible from other nurse-led clinics in the UK. Finally, there has been no economic assessment of nurse-led rheumatology clinics in the UK and so we do not know if they are economically effective.

The aims of this study are to establish whether nurse-led rheumatology clinics are clinically effective and cost effective for patients with rheumatoid arthritis.

2. Methods {#sec0010}
==========

2.1. Study design {#sec0015}
-----------------

This is a pragmatic trial in a complex clinical environment and is conducted over 4 years as a multi-centred RCT. Patients are randomised using an office hours remote secure telephone randomisation service provided by the Clinical Trials and Research Unit, University of Leeds. Patients who fulfil the eligibility criteria and have provided written informed consent are randomised on a 1:1 basis to either Nurse-led clinic (experimental group) or a rheumatologist-led clinic (control group). Randomisation is by random permuted blocks, using the stratification factors, centre and DAS28 score (low ≤3.2 or moderate to severe \>3.2) at baseline. After recruitment, patients have 5 follow-up visits over 12 months. ([Fig. 1](#fig0005){ref-type="fig"}). The methods are consistent with current guidelines on design, conduct and analysis of pragmatic randomised clinical trials ([@bib0095; @bib0155; @bib0170; @bib0235]), and those explicitly for non-inferiority trials ([@bib0015; @bib0140]).

2.2. Study population {#sec0020}
---------------------

The study comprises 180 patients with rheumatoid arthritis recruited from 10 rheumatology centres throughout the UK. Patients with both stable and active disease are included as this reflects the practice of clinical nurse specialists in the UK and Europe and so make the results more meaningful. All patients are seen in one of the 10 participating centres. The centres are distributed throughout the UK and this provides a socio-demographic mix of patients. Inclusion criteria are: a positive diagnosis of rheumatoid arthritis as defined by the American Rheumatism Association ([@bib0005]); aged 18 years or above, and ability to complete questionnaires unaided. Exclusion criteria are: patients unwilling to be randomised to a nurse-led clinic or rheumatologist-led clinic; patients suffering from unstabilised concomitant disease; patients awaiting surgery and patients who have already received care from the practitioners involved in the study.

2.3. Hypothesis {#sec0025}
---------------

The hypothesis is that the outcomes from nurse-led clinics will not be inferior to those obtained by the rheumatologist-led clinics, but at a lower cost and greater patient satisfaction.

3. Interventions {#sec0030}
================

Following randomisation, patients are given appointments with their respective practitioners for weeks 0, 13, 26, 39 and 52. When patients arrive at the clinic, they are seen by an independent assessor who oversees the completion of pain Visual Analogue Scale (VAS), fatigue VAS, the length of morning stiffness and performs joint counts for Disease Activity Score (DAS28). The independent assessor also gives the patient their blood form, questionnaires in a freepost return envelope and sends them to the waiting area ready to see their allocated practitioner. The joint examination for DAS28 can be prone to inter-observer variation and training or agreement sessions have been shown to minimise this ([@bib0045; @bib0175]). Therefore a training session was conducted (by MN) with the independent assessors at the study set-up meeting to ensure standardisation. The joint examination technique was based on the European League Against Rheumatism handbook of clinical assessment in rheumatoid arthritis ([@bib0215]). Since this is a pragmatic trial, the practitioners in both arms of the trial (Clinical Nurse Specialists and the Rheumatologists) did not receive any more training; they manage their patients according to their normal practice.

During the consultation, the clinical nurse specialists record their interventions in a standard "consultation checklist" especially designed for this study. The nurse-led care interventions may include: pain control, medication and dosage changes, intra-articular or intra-muscular steroid injections, provision of patient education or psychosocial support, prescription of splints, non-protocol blood tests or radiographic examination. Other interventions such as referral to the admission ward, to the rheumatologist, physiotherapists, podiatrist or any other health care professional may be carried out as appropriate. The referrals, conferrals and the length of consultation are also recorded.

Patients randomised to the rheumatologist-led care (control group) also have the same number of study visits and the rheumatologist provides care as per normal practice noting all the interventions and referrals in the consultation checklist.

4. Outcome measures {#sec0035}
===================

4.1. Primary and secondary outcomes {#sec0040}
-----------------------------------

The primary outcome measure is the DAS28 ([@bib0150]), an internationally recognised measurement of disease activity in rheumatoid arthritis. It is a composite measurement comprising objective (number of swollen joints and erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) and subjective (number of tender joints and patients global assessment) indices. DAS28 score has been shown to be a strong predictor of physical disability and radiological progression and a sensitive discriminator between patients with high and low disease activity ([@bib0145; @bib0205]). DAS28 score is widely used in making decisions about treatment effectiveness and it forms the basis for the European League against Rheumatism response criteria for rheumatoid arthritis ([@bib0210]). Scores can range from 0 to 9.4, assuming that an ESR of 100 is taken as the upper limit. Levels of disease activity are defined as DAS28 ≤3.2 mild; DAS28 \>3.2 and ≤5.1 moderate; DAS28 \>5.1 severe ([@bib0205; @bib0210]). The DAS28 will be measured at baseline and 13, 26, 39 and 52 weeks.

Secondary measures include haematological, clinical and questionnaire data. The haematological and clinical measures comprise: CRP or ESR, pain intensity (using 10 cm VAS), duration of morning stiffness (hours/minutes) and Fatigue (10 cm VAS). The following questionnaires will be administered at baseline, 26 and 52 weeks:•Health Assessment Questionnaire ([@bib0075])•Hospital Anxiety and Depression Scale ([@bib0230])•Leeds Satisfaction Questionnaire ([@bib0060])•The Arthritis Self Efficacy Scale ([@bib0090])•Rheumatoid Arthritis Quality of Life Questionnaire ([@bib0035])

An additional questionnaire, the EQ-5D ([@bib0190]) will be completed at baseline and weeks 13, 26, 39 and 52 to provide health data for the economic analysis

4.2. Power calculations {#sec0045}
-----------------------

A change in DAS28 score of 1.2 or more is deemed a clinically significant improvement, and a change of 0.6 or more reflects a moderate improvement ([@bib0220]). A change in DAS28 score of 0.6 is assigned as the 'inferiority'/'non-inferiority' margin. Thus:Null hypothesis (inferiority): mean ΔDAS28~RLC~ − mean ΔDAS28~NLC~ ≥ 0.6.Alternative hypothesis (non-inferiority): mean ΔDAS28~RLC~ − mean ΔDAS28~NLC~ \< 0.6.Where Δ = change in, RLC = Rheumatologist-led clinic and NLC = Nurse-led clinic.

A total sample size of 180 participants (90 per treatment arm) is needed to reject the null hypothesis of 'inferiority', given 90% power and 1-sided statistical testing with 2.5% significance level (and a pre-hypothesized standard deviation in DAS28 change scores of 1.5). This total sample size assumes a 10% drop out/non-response rate. The calculation is based on a repeated-measures (pooled) analysis of between-group differences averaged over 4 equidistant follow up time points (13, 26, 39 and 52 weeks). The sample size calculation assumes that the intra-class correlation coefficient (for the correlation of observations over time within individuals) will be about 0.5.

5. Statistical analysis {#sec0050}
=======================

5.1. Statistical analysis {#sec0055}
-------------------------

Analyses will be carried out using both intention to treat and per protocol methods as advocated in extended CONSORT guidelines ([@bib0140]). Difference in mean summary scores will be presented with a 95% two-sided confidence interval from which we can draw a conclusion as to whether to accept or reject the null hypothesis of 'inferiority' regarding the nurse-led care intervention compared to the rheumatologist-led care. The primary outcome measure (DAS28 change score) and secondary measures will be compared between the two groups using data pooled over time; the evaluation focusing on the comparability of average change in DAS28 over the assessed follow up period. Secondary measurement will focus on individual time points. Analysis will be by hierarchical repeated measures modelling. Analysis will adjust for age, gender, centre, baseline DAS28 (and corresponding baseline values for secondary outcomes). Multiple imputation will be used to address the issue of missing data ([@bib0165]). Analysis will also be carried out investigating outcome in relation to the interaction of intervention group and specific baseline variables: age, gender and DAS28.

5.2. Economic evaluation {#sec0060}
------------------------

The economic assessment will encompass both a cost utility analysis and a cost effectiveness analysis ([@bib0015; @bib0155]). A tiered approach to the evaluation will encompass the following economic perspectives: (i) NHS; (ii) healthcare \[NHS plus direct patient costs\]; (iii) societal \[direct (healthcare) plus indirect (productivity) costs\].

Healthcare resource use, specifically in relation to rheumatoid arthritis, is derived through clinic audits and follow up patient questionnaires, and embraces health professional consultations (primary and secondary care), hospital admissions (day care, inpatient stays, A&E visits), investigations, and treatments including over-the-counter medications. Costs will be derived from sources of 'national average' costs ([@bib0030; @bib0115]), and also by direct elicitation from the self-report questionnaires for private out-of-pocket expenditure on health care service use, travel, medication, aids and special dietary requirements. Data collected from each patient on employment status and job title (classified according to its socioeconomic classification using the Office of National Statistics (ONS) approach ([@bib0125; @bib0130])) will be used to determine productivity losses using the human capital approach by multiplying a patient\'s reported number of days off work by the expected average daily wage extracted from National Statistics survey databases ([@bib0120]). Multiple imputation will be used to address missing cost data ([@bib0165]). Health outcomes will be assessed through QALYs derived from the EQ-5D for the cost utility analysis, and the DAS28 change score for the cost effectiveness analysis (with incremental differences in cost being evaluated in relation to the non-inferiority margin of 0.6 in mean DAS28 change).

Between-group economic comparisons will focus on the joint estimation of incremental costs and effects. The precision of the estimates will be ascertained by calculating confidence intervals around effect and cost differences, derived through adjusted linear regression modelling. Data for costs are usually right-skewed, and will therefore be analysed using the preferred bootstrap technique ([@bib0050; @bib0085; @bib0105]). Uncertainty around the cost-effect estimates will be shown graphically using cost effectiveness/utility planes ([@bib0020]). Cost-acceptability curves will be used to help make informative decisions regarding the cost-effectiveness of the nurse clinics at variable ceiling willingness-to-pay cost thresholds ([@bib0185]) Sensitivity analyses will establish the robustness of findings to various assumptions (e.g. imputed versus complete-case data).  

*Funding*: This research is carried out by funding from the Arthritis Research UK grant. It is hosted by the University of Leeds and it has been adopted by the National Institute for Health Research Clinical Research Network.

*Conflict of interest*: None declared.

*Study registration and ethical approval*: The study is registered as a clinical trial at the International Standard Randomised Controlled Trial Number Register (ISRCTN29803766). Multicentre ethical approval was obtained from the Leeds West Research Ethics Committee and site specific approvals were obtained from Local Research Ethics Committees of the 10 participating centres. The study is being conducted in accordance with good clinical practice in research to the Research Governance Framework for Health and Social Care ([@bib0040]).

![Study design.](gr1){#fig0005}
